These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22243597)

  • 1. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing.
    Messing EM; Albertsen P; Andriole GL; Carroll PR; Klein EA
    Urol Oncol; 2012; 30(1):117-9. PubMed ID: 22243597
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.
    Kwiatkowski M; Klotz L; Hugosson J; Recker F
    Eur Urol; 2012 Apr; 61(4):851-4. PubMed ID: 22285762
    [No Abstract]   [Full Text] [Related]  

  • 3. Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.
    Schröder FH
    N Engl J Med; 2011 Nov; 365(21):1953-5. PubMed ID: 22029756
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.
    Brett AS; Ablin RJ
    N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759
    [No Abstract]   [Full Text] [Related]  

  • 5. Psychological research and the prostate-cancer screening controversy.
    Arkes HR; Gaissmaier W
    Psychol Sci; 2012 Jun; 23(6):547-53. PubMed ID: 22555966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One man at a time--resolving the PSA controversy.
    McNaughton-Collins MF; Barry MJ
    N Engl J Med; 2011 Nov; 365(21):1951-3. PubMed ID: 22029758
    [No Abstract]   [Full Text] [Related]  

  • 8. The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--point.
    Ablin RJ
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):391-4. PubMed ID: 22315362
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
    Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
    Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Task force's prevention advice proves hard to swallow. Interview by Eliot Marshall.
    Moyer V
    Science; 2012 Sep; 337(6101):1468-70. PubMed ID: 22997318
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.
    Prasad SM; Drazer MW; Huo D; Hu JC; Eggener SE
    JAMA; 2012 Apr; 307(16):1692-4. PubMed ID: 22535850
    [No Abstract]   [Full Text] [Related]  

  • 13. Grading the new US Preventive Services Task Force prostate cancer screening recommendation.
    Volk RJ; Wolf AM
    JAMA; 2011 Dec; 306(24):2715-6. PubMed ID: 22203540
    [No Abstract]   [Full Text] [Related]  

  • 14. Early detection of prostate cancer. Role of prostate-specific antigen.
    Prabhakaran VM
    Can Fam Physician; 1996 Apr; 42():709-12. PubMed ID: 8653039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
    Eapen RS; Herlemann A; Washington SL; Cooperberg MR
    Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
    BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
    Joshi SS; Filson CP
    Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066
    [No Abstract]   [Full Text] [Related]  

  • 18. Counseling patients about prostate cancer screening.
    Foxhall LE; Von Eschenbach AC
    Am Fam Physician; 2002 May; 65(9):1752, 1754, 1757. PubMed ID: 12018801
    [No Abstract]   [Full Text] [Related]  

  • 19. PSA test not recommended by Canadian Task Force.
    Tanday S
    Lancet Oncol; 2014 Dec; 15(13):e589. PubMed ID: 25499287
    [No Abstract]   [Full Text] [Related]  

  • 20. To screen or not to screen: US Preventive Services Task Force's draft guidelines add to prostate cancer screening debate.
    Printz C
    Cancer; 2012 Apr; 118(8):1959-61. PubMed ID: 22488666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.